Argent Biopharma Share Discussion Threads

[dr biotech] 10/4/2024 21:50

Argent bio pharma is not related to regen, other than having the same ticker..

[greedfear] 10/4/2024 21:39

Not long enough, I still remember this debacle. :)
GL holders!

[lean5gb] 10/4/2024 18:02

Got mine, but I think the share price was around 0.4p when they delisted. I'll stand corrected, but it was a long, long time ago..:0))))

[greedfear] 10/4/2024 16:49

All I have to do now is to find my share certificates. :(

[greedfear] 10/4/2024 16:47

Finally……; RICH !
It was worth the wait!

[blackhorse23] 10/4/2024 15:22

Money moving to APH [alliance pharma] , dividend announcement in 7 days

[smcl] 10/4/2024 12:23

Nothing to do with ReGen therapeutics??

[lean5gb] 10/4/2024 12:08

IT'S ALIVE.! ! !

[lean5gb] 10/4/2024 12:03

..... Ayee up..:0))))))

[greedfear] 23/12/2022 16:51

Merry Christmas all!

[lean5gb] 09/11/2018 14:46

........ Hmmmmm...
.
.
.
.
....... (nah).
.
.
.
.... I might check back here in another five years.

[tom5boy] 12/9/2018 21:41

Maybe just maybe there may be a glimmer of hope for us shareholders.

See website announcement regarding sell to Sterling.

[greedfear] 29/8/2017 17:34

Nothing to add to my latest post. So that you know.

[asmodeus] 29/4/2016 18:06

Some punishment gluttons might like to have a look at Tiziana (TILS), It seems to be taking off !

[stenick] 03/3/2016 08:20

For anyone interest, from Rgt accounts.

Revenues from sales of ColostrininTM for the year to 31 December 2014 were £17,000 (2012 - £52,000). Administrative costs have come down from £179,000 last year to £95,000 in 2014. Overheads have again been kept to a minimum. It should also be noted that within this figure there are non-cash items of £80,000 compared with £155,000 in 2013. These charges represent depreciation of the filtration rig (£27,000), the amortisation of patents (£44,000) and the amortisation of goodwill (£9,000). As a result of these factors the loss for the period after tax amounted to £100,000 (2013 - £171,000).

On the 17th May 2012 the Company drew down the last £40,000 of the £240,000 loan facility available from Alexander David Investments PLC. With interest this has now accrued to a debt of £322,000 as at 31 December 2014 and interest continues to accrue. Technically this convertible loan could now be called upon after 14th February 2014. As previously stated this loan was taken over by Tiziana Life Sciences Plc after their acquisition of Alexander David Investments Plc (“ADI”). Discussions with Tiziana management have clarified that they do not intend to call in this loan but would convert this loan to RGTL shares at an appropriate time.

Sales are down from last year mainly as a result of an order not being placed by our US distributor during 2014, although an order was placed in early 2015. We are working with a new licensee in India to secure regulatory approval to distribute the product direct to consumers there. The application has been with the regulatory agency for some months and a decision is expected soon.

Our USA licensee Metagenics introduced a Colostrinin combination product (CerivaTM) via the 'professional' channel in summer 2014. Active ingredient for this launch stock was the main source of RGTL revenue in 2013. Detailed information is unavailable from Metagenics to ascertain how well the product is being received in the marketplace but the fact that they have recently suggested that no more material will be required during the remainder of 2015 or during the early part of 2016 suggests that the product is not selling as well as was hoped.

Having obtained regulatory approval to do so, Tagerr our distributor in Poland have now switched from distributing product made by Metagenics to tablets supplied by RGTL.These are being well received but obviously sales here are on a modest scale.


Cost saving initiatives continue. The Company runs from a virtual office. Both Directors and consultants remain unpaid (since December 2012) and will continue to defer their remuneration/fees until there is funding/finance available.

The Directors continue to explore various ways of financing and developing the company with its advisers and contacts in order to secure a viable future for the Company in the best interest of shareholders. This includes the outright sale of the Company to a buyer that has the resources to fully exploit the sales potential of Colostrinin. So far a serious potential buyer has not been identified.

[asmodeus] 29/2/2016 11:36

I suspect that I am not alone in having given up all hope with this dream, and decided to waste no more time on it. So can only suggest contacting Tixiana Life Sciences (TILS), who I think own the remains, and may be able to help you, Ted.

[tedfox3] 20/2/2016 12:42

Hello you guys, if anyone reads this sometime in the distant future, i would be grateful on an update of the situation, as i have/had? shares, but haven't been here for years. are they around? are the pills still in tim shilton's lock up lol Any info would be appreciated.

[asmodeus] 03/1/2016 11:19

02 Jan 2016
Company Website changed:
Was: Unknown
Now:

[impala391] 18/6/2015 13:15

Perhaps tiziana, the new owners, want to keep it running? IMO

[asmodeus] 13/5/2015 11:54

Further to the above - according to "Companies in the UK), the "Notice of striking-off action" has been discontinued. Anybody there?

[asmodeus] 15/4/2015 10:09

Apparently "there is a proposal to strike-off" for Regen Therapeutics. I don't know where to look for further information on this. Does anyone else who might glimpse this thread?

[impala391] 06/4/2015 12:15

To busy raising cash ?

[asmodeus] 06/4/2015 10:50

Reports on Tiziana Life Sciences from "Companies in the UK":

05 Apr 2015
New Company Document Available
Form: TM01 - Termination of appointment of director
APPOINTMENT TERMINATED, DIRECTOR ANDREW GUTMANN
Purchase a copy of this document for £4.99 VAT

New Company Document Available
Form: AP01 - Appointment of director
DIRECTOR APPOINTED PROF CHRISTOPHER MCGUIGAN
Purchase a copy of this document for £4.99 VAT

New Company Document Available
Form: AP01 - Appointment of director
DIRECTOR APPOINTED DR KUNWAR SHAILUBHAI
Purchase a copy of this document for £4.99 VAT



The Company's Annual Return is now OVERDUE
The return was expected to be submitted by 11 Mar 2015

[impala391] 17/3/2015 18:32

Time has stood still for Rgt.

[greedfear] 08/3/2015 20:57

Time flies LOL